5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%

被引：0
|
作者：
Gadgeel, S. [1 ]
Rodriguez-Abreu, D. [2 ]
Halmos, B. [3 ]
Garassino, M. C. [4 ,5 ]
Kurata, T. [6 ]
Cheng, Y. [7 ]
Jensen, E. [8 ]
Shamoun, M. [8 ]
Rajagopalan, K. [8 ]
Paz-Ares, L. [9 ,10 ]
机构：
[1] Henry Ford Hlth, Dept Internal Med, Henry Ford Canc Inst, Detroit, MI USA
[2] Univ Los Palmas de Gran Canaria, CHU Insular Materno Infant Gran Canaria, Las Palmas Gran Canaria, Spain
[3] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY USA
[4] Univ Chicago Med & Biol Sci, Thorac Oncol Program, Chicago, IL USA
[5] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[6] Kansai Med Univ Hosp, Dept Thorac Oncol, Osaka, Japan
[7] Jilin Canc Hosp, Dept Oncol, Changchun, Jilin, Peoples R China
[8] Merck Co Inc, Rahway, NJ USA
[9] Univ Complutense Madrid, Univ 12 Octubre, H12OCNIO Lung Canc Unit, Madrid, Spain
[10] Ciberonc, Madrid, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
pembrolizumab; NSCLC; PD-L1-negative;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA14.05
引用
收藏
页码：S77 / S78
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598
    Boyer, M.
    Mclean, J.
    Xu, L.
    Samkari, A.
    Carbone, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S462 - S462
  • [2] Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up
    Abreu, D. Rodriguez
    Reck, M.
    Sendur, N.
    Park, K.
    Lee, D. H.
    Cicin, I.
    Yumuk, P. F.
    Orlandi, F. J.
    Leal, T. A.
    Soparattanapaisarn, N.
    Langleben, A.
    Califano, R.
    Medgyasszay, B.
    Hsia, T-C.
    Otterson, G. A.
    Woods, T.
    Jensen, E.
    Samkari, A.
    Boyer, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S30 - S31
  • [3] dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%
    Holtzman, Liran
    Moskovitz, Mor
    Urban, Damien
    Nechushtan, Hovav
    Keren, Shoshana
    Reinhorn, Daniel
    Wollner, Mira
    Daher, Sameh
    Rottenberg, Yakir
    Rovitzky, Yulia
    Shochat, Tzippy
    Bar, Jair
    Dudnik, Elizabeth
    CLINICAL LUNG CANCER, 2022, 23 (02) : 122 - 134
  • [4] Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Leal, Ticiana A.
    Riess, Jonathan W.
    Jensen, Erin
    Zhao, Bin
    Pietanza, M. Catherine
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2339 - +
  • [5] KEYNOTE-024 Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC with PD-L1 Tumor Proportion Score ≥50%
    Brahmer, J.
    Rodriguez-Abreu, D.
    Robinson, A.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M.
    Rao, S.
    Hotta, K.
    Riccio, A.
    Yang, J.
    Pietanza, M. C.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S153 - S153
  • [6] KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
    Brahmer, J. R.
    Rodriguez-Abreu, D.
    Robinson, A. G.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M.
    Rao, S.
    Hotta, K.
    Leal, T. A.
    Riess, J. W.
    Jensen, E.
    Zhao, B.
    Pietanza, M. C.
    Reck, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1181 - S1182
  • [7] Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
    Boyer, M.
    Sendur, M. A. N.
    Rodriguez-Abreu, D.
    Park, K.
    Lee, D. H.
    Cicin, I.
    Yumuk, P. F.
    Orlandi, F.
    Leal, T.
    Molinier, O.
    Soparattanapaisam, N.
    Langleben, A.
    Califano, R.
    Medgyasszay, B.
    Hsia, T.
    Otterson, G.
    Xu, L.
    Piperdi, B.
    Samkari, A.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S61 - S62
  • [8] Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.
    Sendur, Mehmet Nahit
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Park, Keunchil
    Lee, Dae Ho
    Cicin, Irfan
    Yumuk, Perran Fulden
    Orlandi, Francisco J.
    Leal, Ticiana A.
    Molinier, Olivier
    Soparattanapaisarn, Nopadol
    Langleben, Adrian
    Califano, Raffaele
    Medgyasszay, Balazs
    Hsia, Te-Chun
    Otterson, Gregory Alan
    Xu, Lu
    Burke, Thomas A.
    Samkari, Ayman
    Boyer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
    Velcheti, Vamsidhar
    Rai, Pragya
    Kao, Yu-Han
    Chirovsky, Diana
    Nunes, Ana Tablante
    Liu, Stephen, V
    CLINICAL LUNG CANCER, 2024, 25 (06)
  • [10] The efficacy of pembrolizumab vs nivolumab plus ipilimumab in metastatic NSCLC in relation to PD-L1 and TMB status
    Shalata, W.
    Maimon, N.
    Agbarya, A.
    Yaakobson, A.
    Dudnik, Y.
    Cohen, A. Y.
    Meirovitz, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S849 - S850
12345